Read by QxMD icon Read

Vaccine HPV

Dexter L Cooper, Tiffany Zellner-Lawrence, Mohamed Mubasher, Ananya Banerjee, Natalie D Hernandez
Human papillomavirus (HPV) awareness and vaccination among males in the general population is low. Men in general, but particularly racial/ethnic men, are disproportionately affected by HPV. The purpose of this article is to examine college males' (a) HPV awareness, (b) sexual behaviors, and (c) intention to receive the HPV vaccination. A non-probability sample of all students who self-reported their race/ethnicity and were attending a university in Southeastern United States were contacted by the university registrar's office and recruited to participate in the 15-minute survey...
November 2018: American Journal of Men's Health
Shuihong Yao, Jingyun Xu, Kaixuan Zhao, Pengxia Song, Qin Yan, Weifei Fan, Wan Li, Chun Lu
While the application of early screening and HPV vaccines has reduced the incidence and mortality rates of cervical cancer, it remains the third most common carcinoma and fourth leading cause of cancer-associated death among women worldwide. The precise mechanisms underlying progression of cervical cancer are not fully understood at present. Here, we detected significant down-regulation of 15-hydroxyprostaglandin dehydrogenase (HPGD) in cervical cancer tissues. Overexpression of HPGD inhibited cervical cancer cell proliferation, migration and anchorage-independent growth to a significant extent...
October 17, 2018: Cell Death & Disease
Douglas G Widman, Savanna Gornisiewicz, Sharon Shacham, Sharon Tamir
Infection of immunocompromised individuals with normally benign opportunistic viruses is a major health burden globally. Infections with viruses such as Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), Kaposi's sarcoma virus (KSHV), adenoviruses (AdV), BK virus (BKPyV), John Cunningham virus (JCPyV), and human papillomavirus (HPV) are significant concerns for the immunocompromised, including when these viruses exist as a co-infection with human immunodeficiency virus (HIV). These viral infections are more complicated in patients with a weakened immune system, and often manifest as malignancies resulting in significant morbidity and mortality...
2018: PloS One
Cyra Patel, Julia Ml Brotherton, Alexis Pillsbury, Sanjay Jayasinghe, Basil Donovan, Kristine Macartney, Helen Marshall
BACKGROUND: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide. AIM: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine...
October 2018: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
Paulo Ornellas, Antonio Augusto Ornellas
No abstract text is available yet for this article.
September 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Brunno Raphael Iamashita Voris, Carolina Del Negro Visintin, Leonardo O Reis
No abstract text is available yet for this article.
September 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Joan Campbell-Tofte, Aristidis Vrahatis, Knud Josefsen, Jesper Mehlsen, Kaj Winther
In contrast to the insidious and poorly immunogenic human papillomavirus (HPV) infections, vaccination with the HPV virus-like particles (vlps) is non-infectious and stimulates a strong neutralizing-antibody response that protects HPV-naïve vaccinees from viral infection and associated cancers. However, controversy about alleged adverse events following immunization (AEFI) with the vlps have led to extensive reductions in vaccine acceptance, with countries like Japan dropping it altogether. The AEFIs are grouped into chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)...
October 16, 2018: Cellular and Molecular Life Sciences: CMLS
Stefanie J Klug, Marianne van der Sande, Martin Terhardt, Fred Zepp, Marianne Röbl-Mathieu, Jörg Meerpohl, Miriam Wiese-Posselt, Thomas Harder, Ole Wichmann, Anja Takla
No abstract text is available yet for this article.
October 15, 2018: Der Urologe. Ausg. A
Satyavani Kaliamurthi, Gurudeeban Selvaraj, Aman Chandra Kaushik, Ke-Ren Gu, Dong-Qing Wei
Background and aim: Human papillomavirus (HPV) is an oncogenic agent that causes over 90% of cases of cervical cancer in the world. Currently available prophylactic vaccines are type specific and have less therapeutic efficiency. Therefore, we aimed to predict the potential species-specific and therapeutic epitopes from the protein sequences of HPV45 by using different immunoinformatics tools. Methods: Initially, we determined the antigenic potential of late (L1 and L2) and early (E1, E2, E4, E5, E6, and E7) proteins...
2018: Biologics: Targets & Therapy
Gina S Ogilvie, Felicia Phan, Heather N Pedersen, Simon R Dobson, Monika Naus, Elizabeth M Saewyc
BACKGROUND: The human papillomavirus (HPV) vaccine is delivered widely through school-based immunization programs. Some groups have expressed concern that HPV vaccination programs will result in an increase in sexual risk-taking behaviours among adolescents. We aimed to evaluate population-level changes in sexual behaviours before and after implementation of the school-based HPV vaccination program in British Columbia. METHODS: In 2008, a school-based HPV vaccination program for girls was introduced in British Columbia...
October 15, 2018: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
C Rossi, C Vanhomwegen, F Laurent
High-risk oncogenic HPVs (HR-HPV) are associated in men with pre-cancerous anal dysplasia, oropharyngeal, anal and penile cancer. Anogenital warts are induced by low-risk HPVs. These manifestations are increasing among men, and especially in some high-risk groups as men who have sex with men (MSM). This review targets HPV-associated disease epidemiology as well as safety, immunogenicity, and efficacy level of HPV vaccine in men. Obstacle and cost-effectiveness analysis of HPV vaccination are discussed. Three HPV vaccines are currently available in Belgium with the 9-valent (" 9HPV " - 6/11/16/18/31/33/45/52/58) offering protection against most of HPVassociated diseases...
2018: Revue Médicale de Bruxelles
Pranvera Zejnullahu Raçi, Lea Hošnjak, Mario Poljak, Snježana Židovec Lepej, Adriana Vince
OBJECTIVES: Kosovo's current health care system does not support organized nationwide cervical cancer screening and human papillomavirus (HPV) vaccination programs. To date, no reliable data are available on cervical cancer incidence and mortality in Kosovo, or on high-risk HPV (HR-HPV) prevalence and HPV type distribution. Our aim is to determinate the pre-vaccination prevalence and distribution of HR-HPVs and to assesses the associations between sociodemographic characteristics and increased risk of HPV infection in women from Kosovo...
2018: Ginekologia Polska
Helen Sisson, Yvonne Wilkinson
The human papillomavirus (HPV) vaccine is a key intervention in the prevention of HPV infection and associated cancers. This review emphasizes the importance of understanding what influences decision-making about this vaccine. Guided by the work of Whittemore and Knafl, and Pluye and Hong, we identified 25 studies, from which four prominent themes emerged: fear and risk, pain, parental involvement, and involvement of others. Fear of cervical cancer was a strong motivation to receive the vaccine, and the extent of parental involvement also had an impact on decision-making...
October 15, 2018: Journal of School Nursing: the Official Publication of the National Association of School Nurses
Philip E Castle, Xianhong Xie, Xiaonan Xue, Nancy E Poitras, Thomas S Lorey, Walter K Kinney, Nicolas Wentzensen, Howard D Strickler, Emily A Burger, Mark Schiffman
Women previously vaccinated against human papillomavirus (HPV) type 16 and 18 are now reaching the age (21 years) at which cervical-cancer screening is recommended in the U.S. The impact of HPV vaccination on risks of cervical precancer following a positive and negative screen among women aged 21-24 years who just started routine cervical screening are not well described. Therefore, three-year absolute and relative (RR) cumulative risks of cervical intraepithelial neoplasia grade 2 or more severe diagnoses (≥CIN2) and grade 3 or more severe diagnoses (≥CIN3) were estimated for women undergoing cervical screening at Kaiser Permanente Northern California...
October 11, 2018: Preventive Medicine
Vladimir Gilca, Chantal Sauvageau, Gitika Panicker, Gaston De Serres, Manale Ouakki, Elizabeth R Unger
BACKGROUND: Limited data is available on the use of different HPV vaccines in the same subjects. We evaluated the immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent (9vHPV) and one dose of bivalent vaccine (2vHPV) administered in different order versus two doses of 9vHPV vaccine. METHODS: 371 girls and boys aged 9-10 years were randomized (1:1) to receive (I) two doses of 9vHPV or (II) a mixed schedule of 2vHPV + 9vHPV or 9vHPV + 2vHPV with a 6 month interval...
October 9, 2018: Vaccine
Manika Suryadevara, Cynthia A Bonville, Donald A Cibula, Joseph B Domachowske
OBJECTIVE: To develop a program to educate providers, office staff, patients, and parents on life-long cancer prevention strategies, including the use of human papillomavirus (HPV) vaccine to improve adolescent HPV vaccination rates. STUDY DESIGN: A 2-phase program was implemented at 6 pediatric practices across upstate New York. Phase 1 included provider and staff education regarding practice-specific vaccination challenges and discussion of the contents of a study-specific cancer-prevention booklet, which included HPV vaccine information...
October 9, 2018: Journal of Pediatrics
Massimo Giuliani, Alessandra Latini, Manuela Colafigli, Maria Benevolo, Francesca Rollo, Mauro Zaccarelli, Eugenia Giuliani, Domenico Moretto, Amalia Giglio, Giovanni Rezza, Antonio Cristaudo, Maria G Donà
AIM: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population. MATERIALS & METHODS: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test. RESULTS: A total of 49...
October 12, 2018: Future Microbiology
María Inmaculada Rodríguez-Álvarez, Jose L Gómez-Urquiza, Husein Husein-El Ahmed, Luis Albendín-García, Juan Gómez-Salgado, Guillermo A Cañadas-De la Fuente
Human papillomavirus (HPV) is one of the most prevalent sexually transmitted infections. Although the research focus has been on women, men are also affected. Thus, the aim was to estimate the prevalence of HPV in men and to analyse its risk factors. A systematic review with meta-analysis was performed. The main health science databases were consulted. The search terms were was: "papilloma virus AND (prevalence OR risk factors) AND men". The final sample of studies was n = 16 and the men sample for the meta-analysis was n = 18,106...
October 10, 2018: International Journal of Environmental Research and Public Health
Tracey S Adams, Mauricio A Cuello
Diagnosis of a primary vaginal cancer is rare because most of these lesions will be metastatic from another primary site. Although cancer of the vagina is more common in postmenopausal women, an increase in young women being diagnosed with primary vaginal cancer has been reported, especially in countries with a high HIV prevalence. This will be associated with persistence of high-risk HPV infection. The emphasis should be on primary prevention with prophylactic HPV vaccination. Once there is a suspicion of a primary vaginal cancer, this should be confirmed histologically with biopsy...
October 2018: International Journal of Gynaecology and Obstetrics
Neerja Bhatla, Daisuke Aoki, Daya Nand Sharma, Rengaswamy Sankaranarayanan
Since the publication of the last FIGO Cancer Report there have been giant strides in the global effort to reduce the burden of cervical cancer, with WHO announcing a call for elimination. In over 80 countries, including LMICs, HPV vaccination is now included in the national program. Screening has also seen major advances with implementation of HPV testing on a larger scale. However, these interventions will take a few years to show their impact. Meanwhile, over half a million new cases are added each year...
October 2018: International Journal of Gynaecology and Obstetrics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"